What is Biodesix?
Biodesix operates in the United States, focusing on developing and commercializing blood-based diagnostic tests primarily for lung cancer. Their offerings, such as the Nodify Lung Nodule Risk Assessment testing strategy, aim to assist physicians in evaluating the risk of malignancy in patients with suspicious lung nodules, thereby guiding more precise treatment pathways. The company also provides tests like GeneStrat ddPCR and NGS, and VeriStrat, which analyze tumor mutations and immune system states to establish patient prognosis and inform therapeutic decisions. This data-driven approach positions Biodesix at the intersection of diagnostics and personalized medicine.
How much funding has Biodesix raised?
Biodesix has raised a total of $268.4M across 11 funding rounds:
Series C
$7.1M
Series D
$20M
Series E
$38M
Series F
$22M
Debt
$23M
Debt
$2M
Stock Offering
$72M
Stock Offering
$16.3M
Stock Offering
$50M
Series C (2010): $7.1M, investors not publicly disclosed
Series D (2011): $20M, investors not publicly disclosed
Series E (2015): $38M, investors not publicly disclosed
Series F (2016): $22M, investors not publicly disclosed
Debt (2018): $23M led by Innovatus Capital Partners
Debt (2020): $2M supported by PPP
Stock Issuance/Offering (2020): $72M featuring Undisclosed
Stock Issuance/Offering (2022): $16.3M, investors not publicly disclosed
Stock Issuance/Offering (2022): $50M with participation from Lincoln Park Capital
Key Investors in Biodesix
Innovatus Capital Partners
Innovatus Capital Partners is a firm specializing in long-term capital investments, focusing on opportunities created by market volatility and disruptions. They target asset-based investments with strong cash flow and possess expertise in financial engineering and business development.
Lincoln Park Capital
Lincoln Park Capital is an investment group and asset management firm that specializes in opportunistic investing across public and private companies and real estate. They focus on growth and partnership opportunities, with investment types including public markets, private equity, and venture capital.
What's next for Biodesix?
The recent strategic investment in Biodesix signals a strong vote of confidence in the company's growth trajectory and its potential to further penetrate the oncology diagnostics market. With a focus on expanding its diagnostic capabilities and market reach, Biodesix is poised to leverage this capital to enhance its research and development efforts, scale its commercial operations, and potentially explore new therapeutic areas or diagnostic modalities. The company's commitment to providing actionable insights for lung cancer management suggests a future focused on improving patient outcomes through advanced molecular diagnostics.
See full Biodesix company page
